Pulmonx Corporation filed its quarterly report on Form 10-Q with the SEC on November 3, 2026, covering the fiscal quarter ended September 30, 2026.
Key Highlights
- Cash position: Cash and cash equivalents stood at $52,690 thousand as of September 30, 2026, down from $69,751 thousand at December 31, 2025.
- Total assets: Total assets were $110,212 thousand as of September 30, 2026, compared with $129,291 thousand at December 31, 2025.
- Shares outstanding: As of October 29, 2026, there were 43,550,665 shares of common stock outstanding, par value $0.001 per share.
- Accounts receivable: Accounts receivable, net, were $12,014 thousand at September 30, 2026, versus $12,072 thousand at December 31, 2025.
- Inventory: Combined current and long-term inventory totaled $15,436 thousand and $3,793 thousand, respectively, at September 30, 2026.
- Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
Pulmonx Balance Sheet Position for the Quarter Ended September 30, 2026
Pulmonx Corporation (NASDAQ:LUNG), a Delaware-incorporated medical device company headquartered in Redwood City, California, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing presents unaudited condensed consolidated financial statements and management discussion covering the company's operations in products designed to treat severe chronic obstructive pulmonary disease and emphysema.
According to the filing, total current assets declined to $84,061 thousand at September 30, 2026, from $101,684 thousand at December 31, 2025. The largest component of that change was cash and cash equivalents, which fell by $17,061 thousand over the nine-month period. Restricted cash was $257 thousand at the end of the quarter. Property and equipment, net, were reported at $1,761 thousand, down from $2,220 thousand at year-end 2025. Goodwill remained unchanged at $2,333 thousand. Right-of-use assets were $17,039 thousand at September 30, 2026, compared with $18,028 thousand at December 31, 2025.
The filing notes that it contains forward-looking statements subject to substantial risks and uncertainties, including those described in the Risk Factors section, and that actual future results "may be materially different from what we expect." The company stated it undertakes no obligation to update forward-looking statements except as required by law. The filing covers Part I financial information and Part II other information, including an updated Risk Factors section.
What Was Disclosed
Pulmonx filed its September 30, 2026 quarterly report disclosing unaudited balance sheet data, forward-looking statement disclosures, and updated risk factors. Total assets were $110,212 thousand and cash was $52,690 thousand at quarter-end.



Please wait processing your request...